Adocia SA (ADOCY) Kazanmak

Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 77 full-time employees. The company went IPO on 2012-02-20. The firm specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.